{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:09:01Z","timestamp":1795108141061,"version":"4.10.3"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["AES23 - Proyectos I+D+i en Salud - PI23\/00069"],"award-info":[{"award-number":["AES23 - Proyectos I+D+i en Salud - PI23\/00069"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AES23 - Proyectos I+D+i en Salud - PI23\/00069"],"award-info":[{"award-number":["AES23 - Proyectos I+D+i en Salud - PI23\/00069"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among people over 55 years of age globally, being neovascular AMD (nAMD) its most aggressive form. Its treatment consists of the use of drugs that block vascular endothelial growth factor (anti-VEGF). Proteomics may allow the identification of differentially expressed proteins between responders and non-responders to each anti-VEGF drug. Thus, the objective of Pharmacoproteomics in the development of personalised medicine in Age-related Macular Degeneration (PHARPRO-AMD) is to find new proteomic biomarkers, predictive of response to antiangiogenic treatment in patients with nAMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>PHARPRO-AMD is a nationwide, multicentre, prospective, observational study. Treatment-na\u00efve patients with nAMD starting anti-VEGF therapy will be enrolled and followed up for 2 years. During this period, clinical variables will be gathered to classify treatment response. In addition, blood, tear and vitreous and aqueous humour samples will be collected and will undergo a ZenoSWATH proteomic analysis. Relevant biomarkers identified and response classification will be used to perform a multivariate logistic regression and construct receiver operating characteristic curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study is expected to identify a panel of proteomic biomarkers predictive of anti-VEGF treatment response. Integrating data from invasive and non-invasive biological samples may enhance clinical applicability. Once validated, these biomarkers could support the design of future clinical trials on biomarker-guided therapies, helping to optimise treatment regimens and improve visual outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The PHARPRO-AMD study aims to provide proof-of-concept for biomarker-guided anti-VEGF therapy in nAMD, potentially improving vision outcomes. A notable limitation is the exclusion of patients with visual acuity above 73 Early Treatment of Diabetic Retinopathy Study letters, a criterion chosen to reduce potential ceiling effects and improve response assessment accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Approved by the Galician Network of Ethics Committees, with nationwide validity. Anonymised data will be deposited in open-access repositories and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Spanish Clinical Studies Registry (REec) (0033-2024-OBS).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2024-001956","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T01:35:19Z","timestamp":1756085719000},"page":"e001956","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacoproteomics in the development of personalised medicine in Age-related Macular Degeneration (PHARPRO-AMD) study protocol"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2492-0266","authenticated-orcid":false,"given":"Antonio","family":"Ca\u00f1izo-Outeiri\u00f1o","sequence":"first","affiliation":[{"name":"FarmaCHUSLab Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain"},{"name":"Pharmacy Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5281-5694","authenticated-orcid":false,"given":"Diana Carolina","family":"Castro-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"FarmaCHUSLab Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-5576","authenticated-orcid":false,"given":"Luis","family":"Arias-Barquet","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5675-9356","authenticated-orcid":false,"given":"Mar\u00eda Isabel","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3178-7419","authenticated-orcid":false,"given":"Nuria","family":"Olivier-Pascual","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, University Hospital Complex of Ferrol, Ferrol, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8917-5525","authenticated-orcid":false,"given":"Ignacio","family":"Ortea","sequence":"additional","affiliation":[{"name":"Proteomics Unit, Centro de Investigaci\u00f3n en Nanomateriales y Nanotecnolog\u00eda (CINN-CSIC), Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-4227","authenticated-orcid":false,"given":"Salvador","family":"Pastor-Iodate","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Valladolid University Hospital, Valladolid, Spain"},{"name":"Institute of Applied Ophthalmobiology (IOBA), University of Valladolid (UVa), Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7630-4252","authenticated-orcid":false,"given":"Enrique","family":"Rodr\u00edguez-De la R\u00faa-Franch","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Virgen Macarena University Hospital, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-0788","authenticated-orcid":false,"given":"Jos\u00e9 M","family":"Ruiz-Moreno","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6664-6275","authenticated-orcid":false,"given":"\u00d3scar","family":"Ruiz-Moreno","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Miguel Servet University Hospital, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-4535","authenticated-orcid":false,"given":"Manuel","family":"S\u00e1enz de Viteri-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, University Clinic of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5792-6937","authenticated-orcid":false,"given":"Anna","family":"Sala-Puigdollers","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PHARPRO-AMD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7348-7337","authenticated-orcid":false,"given":"Anxo","family":"Fern\u00e1ndez-Ferreiro","sequence":"additional","affiliation":[{"name":"FarmaCHUSLab Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain"},{"name":"Pharmacy Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,24]]},"reference":[{"key":"2026010721210938000_10.1.e001956.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314422"},{"key":"2026010721210938000_10.1.e001956.2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2174\/0929867326666190711105325","article-title":"Anti-VEGF Treatment and Response in Age-related Macular Degeneration: Disease\u2019s Susceptibility, Pharmacogenetics and Pharmacokinetics","volume":"27","author":"Maro\u00f1as","year":"2020","journal-title":"CMC"},{"key":"2026010721210938000_10.1.e001956.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.08.035"},{"key":"2026010721210938000_10.1.e001956.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00265-2"},{"key":"2026010721210938000_10.1.e001956.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04404-0"},{"key":"2026010721210938000_10.1.e001956.6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/0929867326666190726121711","article-title":"Pharmacological Advances in the Treatment of Age-related Macular Degeneration","volume":"27","author":"Gil-Mart\u00ednez","year":"2020","journal-title":"Curr Med Chem"},{"key":"2026010721210938000_10.1.e001956.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"J Transl Med"},{"key":"2026010721210938000_10.1.e001956.8","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12463"},{"key":"2026010721210938000_10.1.e001956.9","doi-asserted-by":"crossref","DOI":"10.1007\/s10792-025-03525-2","article-title":"Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy","volume":"45","author":"Bleidi\u00dfel","year":"2025","journal-title":"Int Ophthalmol"},{"key":"2026010721210938000_10.1.e001956.10","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13154375","article-title":"Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness","volume":"13","author":"Hirayama","year":"2024","journal-title":"J Clin Med"},{"key":"2026010721210938000_10.1.e001956.11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.oret.2025.02.002","article-title":"Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration","volume":"9","author":"Bala","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"2026010721210938000_10.1.e001956.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-021-01841-6","article-title":"Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration","volume":"21","author":"Razavi","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"2026010721210938000_10.1.e001956.13","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.65.11.15","article-title":"Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab","volume":"65","author":"Todoroki","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026010721210938000_10.1.e001956.14","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.48"},{"key":"2026010721210938000_10.1.e001956.15","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/s41433-022-02095-2","article-title":"The Royal College of Ophthalmologists Commissioning guidelines on age macular degeneration: executive summary","volume":"36","author":"Chandra","year":"2022","journal-title":"Eye (Lond)"},{"key":"2026010721210938000_10.1.e001956.16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314759","article-title":"Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review","volume":"23","author":"Garc\u00eda-Quintanilla","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026010721210938000_10.1.e001956.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-021-02152-6","article-title":"Aqueous humor cytokine levels through microarray analysis and a sub-analysis based on optical coherence tomography in wet age-related macular degeneration patients","volume":"21","author":"Joo","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"2026010721210938000_10.1.e001956.18","doi-asserted-by":"crossref","first-page":"692272","DOI":"10.3389\/fmed.2021.692272","article-title":"Novel Possible Protein Targets in Neovascular Age-Related Macular Degeneration: A Pilot Study Experiment","volume":"8","author":"Coronado","year":"2022","journal-title":"Front Med"},{"key":"2026010721210938000_10.1.e001956.19","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144469","article-title":"Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy","volume":"132","author":"Cao","year":"2022","journal-title":"J Clin Invest"},{"key":"2026010721210938000_10.1.e001956.20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97818","article-title":"Therapeutic drug repositioning using personalized proteomics of liquid biopsies","volume":"2","author":"Velez","year":"2017","journal-title":"JCI Insight"},{"key":"2026010721210938000_10.1.e001956.21","doi-asserted-by":"crossref","first-page":"108942","DOI":"10.1016\/j.exer.2022.108942","article-title":"Proteomic changes of aqueous humor in proliferative diabetic retinopathy patients treated with different intravitreal anti-VEGF agents","volume":"216","author":"Chen","year":"2022","journal-title":"Exp Eye Res"},{"key":"2026010721210938000_10.1.e001956.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2026010721210938000_10.1.e001956.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2026010721210938000_10.1.e001956.24","unstructured":"Ministerio de Sanidad G de E . Cat\u00e1logo nacional de hospitales. 2024."},{"key":"2026010721210938000_10.1.e001956.25","unstructured":"Ministerio de Sanidad G de E . Sistema de informaci\u00f3n de atenci\u00f3n primaria: resumen gr\u00e1fico 2022. Recursos, poblaci\u00f3n asignada y actividad en atenci\u00f3n primaria; 2022."},{"key":"2026010721210938000_10.1.e001956.26","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14388"},{"key":"2026010721210938000_10.1.e001956.27","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.64.13.34","article-title":"Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration","volume":"64","author":"Garc\u00eda-Quintanilla","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026010721210938000_10.1.e001956.28","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10051003","article-title":"Biomarkers as Predictive Factors of Anti-VEGF Response","volume":"10","author":"Bobadilla","year":"2022","journal-title":"Biomedicines"},{"key":"2026010721210938000_10.1.e001956.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2023-001516","article-title":"Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response\u2014a scoping review","volume":"9","author":"Dervenis","year":"2024","journal-title":"BMJ Open Ophth"},{"key":"2026010721210938000_10.1.e001956.30","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1007\/s00417-024-06478-x","article-title":"MicroRNA expression profiling in tears and blood as predictive biomarkers for anti-VEGF treatment response in wet age-related macular degeneration","volume":"262","author":"Yen","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721210938000_10.1.e001956.31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.oret.2021.05.002","article-title":"Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema","volume":"5","author":"Gallardo","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"2026010721210938000_10.1.e001956.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-024-03381-1","article-title":"Artificial intelligence in age-related macular degeneration: state of the art and recent updates","volume":"24","author":"Crincoli","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"2026010721210938000_10.1.e001956.33","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-21053"},{"key":"2026010721210938000_10.1.e001956.34","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1109\/JBHI.2020.3000136","article-title":"End-to-End Deep Learning Model for Predicting Treatment Requirements in Neovascular AMD From Longitudinal Retinal OCT Imaging","volume":"24","author":"Romo-Bucheli","year":"2020","journal-title":"IEEE J Biomed Health Inform"},{"key":"2026010721210938000_10.1.e001956.35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/tvst.12.1.18","article-title":"Evaluation of Multiple Machine Learning Models for Predicting Number of Anti-VEGF Injections in the Comparison of AMD Treatment Trials (CATT)","volume":"12","author":"Chandra","year":"2023","journal-title":"Trans Vis Sci Tech"},{"key":"2026010721210938000_10.1.e001956.36","doi-asserted-by":"crossref","DOI":"10.3390\/biom14030252","article-title":"Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization","volume":"14","author":"Fu","year":"2024","journal-title":"Biomolecules"},{"key":"2026010721210938000_10.1.e001956.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.11.004"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2024-001956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:22:10Z","timestamp":1767849730000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2024-001956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,24]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjophth-2024-001956"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2024-001956","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}